ELVN
Enliven Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+11/100
Last price
42.40
▼ 3.07 (6.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
42.50
Prev close
45.47
Day high
45.61
Day low
41.22
Volume
2.33M
Market cap
$3.11B
P/E (TTM)
—
52W range
14.79 – 62.32
Day trading desk
Gap from prior close
-6.53%
Prior close 45.47
VWAP
42.35
+0.12% from price
Relative volume
1.43×
Normal
Session range
13.73%
41.22 – 46.88
Position in range
21%
Near session low
ATR (14D)
2.03
4.78% of price
Prior day high
46.94
PDH
Prior day low
45.23
PDL
Bid / ask spread
—
Quote not published
Session volume
1.59M
Avg 1.11M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-8.86%
-10.8%
1M
-28.54%
-29.7%
3M
-16.56%
-21.1%
6M
-1.78%
-20.0%
YTD
+175.26%
+161.0%
1Y
+116.17%
+99.7%
3Y
+210.32%
+128.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ELVN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-1.17M
Net selling
Buy transactions
11
212.87K shares
Sell transactions
16
1.39M shares
Net transactions
+27
Buys less sells
Sell : buy shares
6.5 : 1
Heavily one-sided
Insider-held shares
4.56M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 1, 26 | GARLAND J SCOTT Director |
SELL | 13.00K | $606.72K | Direct |
| Oct 1, 26 | GARLAND J SCOTT Director |
CONVERSION | 13.00K | $201.11K | Direct |
| Sep 17, 26 | COLLINS HELEN LOUISE Officer |
SELL | 5.00K | $251.75K | Direct |
| Sep 17, 26 | HOHL BENJAMIN Chief Financial Officer |
SELL | 6.02K | $303.00K | Direct |
| Sep 17, 26 | COLLINS HELEN LOUISE Officer |
CONVERSION | 5.00K | $12.40K | Direct |
| Sep 17, 26 | HOHL BENJAMIN Chief Financial Officer |
CONVERSION | 3.98K | $59.13K | Direct |
| Aug 17, 26 | COLLINS HELEN LOUISE Officer |
SELL | 5.00K | $292.93K | Direct |
| Aug 17, 26 | HOHL BENJAMIN Chief Financial Officer |
SELL | 6.02K | $352.55K | Direct |
| Aug 17, 26 | COLLINS HELEN LOUISE Officer |
CONVERSION | 5.00K | $12.40K | Direct |
| Aug 4, 26 | DERYNCK MIKA K Director |
SELL | 158.79K | $9.56M | Direct |
| Aug 4, 26 | DERYNCK MIKA K Director |
CONVERSION | 158.79K | $1.72M | Direct |
| Jul 17, 26 | COLLINS HELEN LOUISE Officer |
SELL | 5.00K | $263.37K | Direct |
| Jul 17, 26 | HOHL BENJAMIN Chief Financial Officer |
SELL | 6.02K | $316.78K | Direct |
| Jul 17, 26 | COLLINS HELEN LOUISE Officer |
CONVERSION | 5.00K | $12.40K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BALLAL RAHUL D. |
Director | 22.34K | Sale |
COLLINS HELEN LOUISE |
Officer | 25.00K | Sale |
GARLAND J SCOTT |
Director | 0 | Sale |
HEYMAN RICHARD A |
Director | — | Sale |
HOHL BENJAMIN |
Chief Financial Officer | 38.00K | Sale |
KINTZ SAMUEL |
Chief Executive Officer | — | Sale |
KUNKEL LORI ANNE |
Director | 41.88K | Sale |
LYSSIKATOS JOSEPH P |
Former | 758.94K | Stock Award(Grant) |
ORBIMED ADVISORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
PATEL ANISH |
Former | 235.01K | Stock Award(Grant) |
Fundamentals
Market cap$3.11B
Enterprise value$2.21B
Revenue (TTM)—
Gross profit—
EBITDA$-124.28M
Net income$-105.93M
EPS (TTM)$-1.56
Free cash flow$-45.26M
Total cash$895.16M
Total debt$1.51M
Book value / share$12.22
Shares outstanding73.27M
Float60.52M
Short % of float16.95%
Dividend yield0.00%
Beta (5Y)0.34
Valuation & profitability ratios
Trailing P/E—
Forward P/E-18.01
PEG ratio—
Price / sales—
Price / book3.47
EV / revenue—
EV / EBITDA-17.80
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-15.31%
Return on assets-11.00%
Debt / equity0.17
Current ratio64.07
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $85.86M | $80.78M | $64.57M | $31.02M | +6.3% |
| Selling, general & admin | $33.80M | $23.78M | $18.95M | $7.77M | +42.2% |
| Total operating expense | $119.66M | $104.55M | $83.53M | $38.79M | +14.4% |
| Operating income | -$119.66M | -$104.55M | -$83.53M | -$38.79M | -14.4% |
| Net interest income | $16.01M | $14.89M | $11.97M | $1.13M | +7.5% |
| Pre-tax income | -$103.69M | -$88.79M | -$71.58M | -$37.66M | -16.8% |
| Tax provision | $0 | $232.00K | $0 | — | -100.0% |
| Net income | -$103.69M | -$89.02M | -$71.58M | -$37.66M | -16.5% |
| Net income to common | -$103.69M | -$89.02M | -$71.58M | -$37.66M | -16.5% |
| Basic EPS | -1.83 | -1.89 | -2.01 | -0.92 | +3.2% |
| Diluted EPS | -1.83 | -1.89 | -2.01 | -0.92 | +3.2% |
| EBIT | -$119.66M | -$104.55M | -$83.53M | -$38.79M | -14.4% |
| EBITDA | -$119.39M | -$104.24M | -$83.23M | -$38.58M | -14.5% |
| Basic shares | 56.66M | 47.07M | 35.55M | 41.10M | +20.4% |
| Diluted shares | 56.66M | 47.07M | 35.55M | 41.10M | +20.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $98.90M | $124.12M | $100.14M | $75.54M | -20.3% |
| Cash & short-term investments | $462.62M | $313.44M | $253.15M | $75.54M | +47.6% |
| Total current assets | $474.88M | $318.13M | $266.15M | $77.75M | +49.3% |
| Property, plant & equipment | $417.00K | $458.00K | $1.06M | $1.52M | -9.0% |
| Total assets | $476.17M | $325.76M | $271.87M | $83.30M | +46.2% |
| Total current liabilities | $16.57M | $15.91M | $25.89M | $9.71M | +4.1% |
| Total debt | $399.00K | $0 | $335.00K | $323.00K | — |
| Total liabilities | $16.57M | $15.91M | $25.96M | $160.12M | +4.1% |
| Retained earnings | -$347.17M | -$243.47M | -$154.45M | -$82.86M | -42.6% |
| Shareholder equity | $459.60M | $309.85M | $245.91M | -$76.83M | +48.3% |
| Working capital | $458.31M | $302.21M | $240.26M | $68.04M | +51.7% |
| Net tangible assets | $459.60M | $309.85M | $245.91M | -$76.83M | +48.3% |
| Shares issued | 59.44M | 48.94M | 41.29M | 41.10M | +21.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$103.69M | -$89.02M | -$71.58M | -$37.66M | — | -16.5% |
| Depreciation & amortisation | $263.00K | $317.00K | $297.00K | $215.00K | — | -17.0% |
| Stock-based compensation | $34.02M | $20.17M | $12.91M | $3.19M | — | +68.6% |
| Change in working capital | -$1.12M | -$4.54M | $1.40M | $438.00K | — | +75.3% |
| Operating cash flow | -$70.30M | -$73.19M | -$61.27M | -$32.08M | — | +3.9% |
| Capital expenditure | -$158.00K | -$44.00K | -$149.00K | -$612.00K | — | -259.1% |
| Investing cash flow | -$173.84M | -$36.00M | -$148.41M | -$612.00K | — | -382.9% |
| Share buybacks | — | — | — | — | -$226.00K | — |
| Financing cash flow | $218.87M | $133.16M | $234.29M | -$1.80M | — | +64.4% |
| Free cash flow | -$70.46M | -$73.24M | -$61.42M | -$32.69M | — | +3.8% |
| End cash position | $98.90M | $124.17M | $100.19M | $75.59M | — | -20.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $29.00M | $20.69M | $21.25M | $18.23M | $21.49M | +40.2% |
| Selling, general & admin | $8.21M | $7.14M | $13.04M | $6.87M | $7.09M | +15.1% |
| Total operating expense | $37.21M | $27.82M | $34.28M | $25.10M | $28.58M | +33.7% |
| Operating income | -$37.21M | -$27.82M | -$34.28M | -$25.10M | -$28.58M | -33.7% |
| Net interest income | $4.73M | $4.20M | $4.62M | $4.95M | $3.25M | +12.8% |
| Pre-tax income | -$32.48M | -$23.63M | -$29.67M | -$20.15M | -$25.34M | -37.5% |
| Tax provision | — | — | $0 | $0 | $0 | — |
| Net income | -$32.48M | -$23.63M | -$29.67M | -$20.15M | -$25.34M | -37.5% |
| Net income to common | -$32.48M | -$23.63M | -$29.67M | -$20.15M | -$25.34M | -37.5% |
| Basic EPS | -0.49 | -0.38 | -0.48 | -0.32 | -0.49 | -28.9% |
| Diluted EPS | -0.49 | -0.38 | -0.48 | -0.32 | -0.49 | -28.9% |
| EBIT | -$37.21M | -$27.82M | -$34.28M | -$25.10M | -$28.58M | -33.7% |
| EBITDA | -$37.20M | -$27.81M | -$34.24M | -$25.03M | -$28.50M | -33.8% |
| Basic shares | 66.17M | 62.80M | 62.21M | 62.09M | 52.10M | +5.4% |
| Diluted shares | 66.17M | 62.80M | 62.21M | 62.09M | 52.10M | +5.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $135.50M | $132.18M | $98.90M | $101.73M | $119.44M | +2.5% |
| Cash & short-term investments | $895.15M | $452.40M | $462.62M | $477.56M | $490.50M | +97.9% |
| Total current assets | $907.34M | $463.14M | $474.88M | $482.68M | $495.62M | +95.9% |
| Property, plant & equipment | $1.64M | $310.00K | $417.00K | $874.00K | $1.03M | +429.7% |
| Total assets | $910.22M | $464.85M | $476.17M | $490.88M | $503.89M | +95.8% |
| Total current liabilities | $14.16M | $11.49M | $16.57M | $14.65M | $15.21M | +23.3% |
| Total debt | $597.00K | $302.00K | $399.00K | $387.00K | $580.00K | +97.7% |
| Total liabilities | $15.07M | $11.49M | $16.57M | $14.75M | $15.41M | +31.2% |
| Retained earnings | -$403.28M | -$370.79M | -$347.17M | -$317.50M | -$297.35M | -8.8% |
| Shareholder equity | $895.15M | $453.37M | $459.60M | $476.12M | $488.47M | +97.4% |
| Working capital | $893.18M | $451.65M | $458.31M | $468.03M | $480.41M | +97.8% |
| Net tangible assets | $895.15M | $453.37M | $459.60M | $476.12M | $488.47M | +97.4% |
| Shares issued | 73.25M | 60.89M | 59.44M | 59.26M | 59.23M | +20.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$32.48M | -$23.63M | -$29.67M | -$20.15M | -$25.34M | — | -37.5% |
| Depreciation & amortisation | $7.00K | $14.00K | $46.00K | $62.00K | $81.00K | — | -50.0% |
| Stock-based compensation | $13.91M | $7.40M | $12.31M | $7.18M | $7.72M | — | +88.1% |
| Change in working capital | -$605.00K | -$3.43M | $1.22M | -$157.00K | $313.00K | — | +82.4% |
| Operating cash flow | -$18.53M | -$19.29M | -$15.84M | -$13.28M | -$17.06M | — | +3.9% |
| Capital expenditure | — | — | — | — | -$139.00K | -$20.00K | — |
| Investing cash flow | -$441.57M | $42.53M | $12.38M | -$4.06M | -$183.59M | — | -1,138.3% |
| Financing cash flow | $463.42M | $10.05M | $623.00K | -$368.00K | $218.38M | — | +4,509.7% |
| Free cash flow | -$18.63M | -$19.29M | -$15.84M | -$13.28M | -$17.20M | — | +3.4% |
| End cash position | $135.50M | $132.18M | $98.90M | $101.73M | $119.44M | — | +2.5% |
Options analytics
Put / call volume
0.04
Call-heavy session
Put / call open interest
0.12
Positioning, not flow
Max pain
45.00
+6.2% from spot
ATM implied vol
53.4%
Nearest strike to spot
Skew (10% OTM)
+58.1%
Puts bid over calls
Call volume
365
Contracts, this expiry
Put volume
15
Contracts, this expiry
Heaviest call OI
45.00
151 contracts
Heaviest put OI
45.00
30 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.38 | -0.49 | -29.8% |
| Mar 2026 | -0.41 | -0.38 | +7.3% |
| Dec 2025 | -0.48 | -0.48 | -1.1% |
| Sep 2025 | -0.47 | -0.32 | +31.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.46 | 6 | $0 | 0.0% |
| Next quarter | -0.58 | 6 | $0 | 0.0% |
| Current year | -1.96 | 6 | $0 | 0.0% |
| Next year | -2.35 | 7 | $5.56K | 0.0% |
Analyst targets & ownership
Mean target$73.67
High target$82.00
Low target$64.00
Implied upside73.74%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy3 / 11
Hold0
Sell / Strong sell0 / 0
Held by insiders6.22%
Held by institutions114.10%
Institutions holding302
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
45.54
-6.90% from price
SMA 20
48.85
-13.23% from price
SMA 50
54.75
-22.57% from price
SMA 100
50.13
-15.41% from price
SMA 200
40.69
+4.18% from price
EMA 12
46.63
-9.08% from price
EMA 26
49.70
-14.69% from price
EMA 50
51.34
-17.41% from price
RSI (14)
24.6
Oversold
MACD (12,26,9)
-3.06
Hist -0.26
ATR (14)
2.03
4.78% of price
Realised vol 30D
40.0%
Annualised
Bollinger upper
57.06
20, 2σ
Bollinger lower
40.65
20, 2σ
50 / 200 cross
Golden
54.75 vs 40.69
Trend bias
Above 200
+4.18%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.96
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
40.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-36.8%
Peak to trough
Max drawdown 5Y
-75.6%
Peak to trough
ATR 14
2.03
4.78% of price
Beta (reported)
0.34
5Y monthly, from filing
Short interest
Shares short
8.62M
Prior 8.26M
Change vs prior
+4.4%
Shorts adding
% of float
16.95%
Elevated
% of shares out
11.77%
Against total outstanding
Days to cover
9.8
Crowded exit
Float
60.52M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | Morgan Stanley | INITIATED | — | Overweight |
| Oct 1, 26 | JP Morgan | INITIATED | — | Overweight |
| Aug 18, 26 | William Blair | INITIATED | — | Outperform |
| Aug 18, 26 | Barclays | INITIATED | — | Overweight |
| Aug 18, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Stifel | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Jul 21, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Jul 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 1, 26 | Stifel | MAINTAINED | Buy | Buy |
| Jun 29, 26 | Jones Trading | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-27
Proxy Statements
PRE 14A · 2026-04-15
Corporate Changes & Voting Matters
8-K · 2026-03-03
Corporate Changes & Voting Matters
8-K · 2026-01-07
Headlines
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
PR Newswire · 7h ago
Morgan Stanley Initiates Enliven Therapeutics at Overweight
MT Newswires · 5d ago
JPMorgan Initiates Enliven Therapeutics at Overweight With $75 Price Target
MT Newswires · 6d ago
Enliven Therapeutics Insider Sold Shares Worth $251,754, According to a Recent SEC Filing
MT Newswires · 15d ago
Enliven Therapeutics Insider Sold Shares Worth $303,003, According to a Recent SEC Filing
MT Newswires · 15d ago
Enliven Therapeutics to Present at Upcoming Investor Conferences
PR Newswire · 33d ago
Miners And More Lead Slew Of Stocks To Watch — With This Line In Focus
Investor's Business Daily · 34d ago
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
PR Newswire · 36d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.